Alpha-9 Oncology
Parita Patel is a seasoned professional in clinical operations, currently serving as Director of Clinical Operations at Kronos Bio since April 2021, after previously holding the position of Associate Director of Clinical Operations. Prior experience includes a tenure at Gilead Sciences as Senior Clinical Trials Manager, overseeing early development programs in various therapeutic areas including Inflammation, Liver diseases, Oncology, and Virology. Parita Patel also excelled as Global Clinical Trial Leader at Genentech, leading a significant cancer immunotherapy trial and collaborating with multiple functions to ensure project success. Additional roles span various clinical management positions at Exelixis, Parexel, PRA Health Sciences, ResearchPoint, INC Research, and CEDRA Clinical Research. Parita Patel earned a degree from The University of Texas at Austin from 2000 to 2004.
This person is not in any teams
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.